MACTER Share Price | Macter International Ltd. Stock Analysis & Recommendation

Mojo Score Change: Macter International Ltd. has changed its score on 24 Mar 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Macter International Ltd. with Similar Stocks

Citi Pharma Ltd.Ferozsons Laboratories Ltd.Hoechst Pakistan Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Debt Company with a Debt to Equity ratio (avg) at 0 times

High Debt Company with a Debt to Equity ratio (avg) at 0 times
The company has been able to generate a Return on Equity (avg) of 13.85% signifying low profitability per unit of shareholders funds

Healthy long term growth as Operating profit has grown by an annual rate 37.00%

The company has declared Positive results for the last 4 consecutive quarters

With ROE of 18.3, it has a attractive valuation with a 5 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PKR 12,030 Million (Small Cap)

P/E

21.00

Industry P/E

Dividend Yield

0.80%

Debt Equity

0.19

Return on Equity

20.23%

Price to Book

3.05

Revenue and Profits:

Net Sales:

3,507 Million

(Quarterly Results - Dec 2025)

Net Profit:

291 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

19.39%

6 Months

-6.63%

1 Year

306.42%

2 Years

268.06%

3 Years

218.22%

4 Years

181.82%

5 Years

319.67%

Macter International Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

15.12%

EBIT Growth (5y)

30.96%

EBIT to Interest (avg)

7.25

Debt to EBITDA (avg)

1.07

Net Debt to Equity (avg)

0.29

Sales to Capital Employed (avg)

2.23

Tax Ratio

42.52%

Dividend Payout Ratio

22.42%

Pledged Shares

Institutional Holding

ROCE (avg)

19.71%

ROE (avg)

13.85%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.70

EV to EBIT

13.73

EV to EBITDA

11.90

EV to Capital Employed

4.12

EV to Sales

1.70

PEG Ratio

0.21

Dividend Yield

0.05%

ROCE (Latest)

30.04%

ROE (Latest)

22.32%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 22.62% vs 6.70% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 100.62% vs -51.37% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,507.30",
          "val2": "2,860.30",
          "chgp": "22.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "689.50",
          "val2": "366.30",
          "chgp": "88.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "31.50",
          "val2": "33.80",
          "chgp": "-6.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "291.50",
          "val2": "145.30",
          "chgp": "100.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "171.40%",
          "val2": "101.20%",
          "chgp": "7.02%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 29.91% vs 15.14% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 95.65% vs 15.31% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,359.90",
          "val2": "7,974.50",
          "chgp": "29.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,548.00",
          "val2": "914.70",
          "chgp": "69.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "134.00",
          "val2": "110.40",
          "chgp": "21.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "786.90",
          "val2": "402.20",
          "chgp": "95.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "122.30%",
          "val2": "82.10%",
          "chgp": "4.02%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

3,507.30

2,860.30

22.62%

Operating Profit (PBDIT) excl Other Income

689.50

366.30

88.23%

Interest

31.50

33.80

-6.80%

Exceptional Items

0.00

Consolidate Net Profit

291.50

145.30

100.62%

Operating Profit Margin (Excl OI)

171.40%

101.20%

7.02%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 22.62% vs 6.70% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 100.62% vs -51.37% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'25

Jun'25

Jun'24

Change(%)

Net Sales

10,359.90

7,974.50

29.91%

Operating Profit (PBDIT) excl Other Income

1,548.00

914.70

69.24%

Interest

134.00

110.40

21.38%

Exceptional Items

0.00

Consolidate Net Profit

786.90

402.20

95.65%

Operating Profit Margin (Excl OI)

122.30%

82.10%

4.02%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2025 is 29.91% vs 15.14% in Jun 2024

Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 95.65% vs 15.31% in Jun 2024

All Annual Results

Company CV

About Macter International Ltd.

Macter International Ltd.

Pharmaceuticals & Biotechnology

Macter International Ltd is a Pakistan-based pharmaceutical company. The Company’s primary activity is to manufacture and market pharmaceutical products. It offers a diversified portfolio of pharmaceutical products covering all therapeutic categories including antibiotics, anti-allergy, cardiovascular and Anti-viral infections. Its offered product under various therapeutic categories, includes DX3 Softgel, Macdronic 5mg, Macdronic 4mg , MAclimta , Milast, MACIVY, MACLINZA, Avelia Sachet, SANTE IV, Maclusa, Nurica, Alenor, Atizox, Bismol, Buphain, Cadla, Carac, Carac-H, Co-Amoxi, Dexodine, Demeco, Dicaine, DX3 Softgel, Ecavir, Epilepsin, Epuram, Esante, Glio, Hart, Heberon Alfa R, Inspirol, Itogaurd, Lefanor, Locril, Locril Plus, Mac-Mether, Macprofen, Macdicol, Macticort, Mitaz, Proberry Probiotic Capsule, Sante Plus, Setzine, Sofomac, Tacip, tio-Veez and Zincasa.

Company Coordinates

Company Details

F-216, S.I.T.E , KARACHI None : 75700

Tel: 92 21 32591000

http://macter.com/

Registrar Details